viewGlaxoSmithKline PLC

GlaxoSmithKline-owned ViiV Healthcare receives green light for long-acting HIV treatment

ViiV’s Vocabria used in combination with Janssen Pharmaceutical’s rilpivirine injection and tablets

GlaxoSmithKline PLC -

ViiV Healthcare, the specialist HIV company majority-owned by GlaxoSmithKline PLC (LON:GSK), has received marketing approval for a long-acting therapy for the condition.

ViiV’s Vocabria used in combination with Janssen Pharmaceutical’s rilpivirine injection and tablets could reduce the treatment days for HIV to once per month or even once every two months from the daily regimen used to keep the illness in check currently.

Following an oral initiation phase, the patients receive a long-acting injection – a first for people living with the virus, which damages the cells in the immune system.

“It will potentially change the treatment experience for some people living with HIV by removing the need for daily HIV tablets,” said ViiV chief executive, Deborah Waterhouse in a statement.

“We are committed to pursuing innovative research to meet the diverse needs of the HIV community, and we won't stop until we have more ways to treat, and hopefully one day cure, HIV," she added.

Quick facts: GlaxoSmithKline PLC

Price: 1190.8 GBX

Market: LSE
Market Cap: £59.91 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Anglo Pacific Group makes a transformational move by acquiring stream on the...

Anglo Pacific Group (TSE: APY- LSE: APF) CEO Julian Treger joined Steve Darling from Proactive with news the company has just announced the biggest deal the company has ever done, acquiring a stream on Vale’s Voisey’s Bay Nickel and Cobalt project in Newfoundland and Labrador for 205...

1 hour, 51 minutes ago

2 min read